Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

A Matched Analysis on the Prognostic Impact of Race on Survival Endpoints of Women with Early-Stage Endometrial Cancer.

Feldman A, Chaugle S, Burmeister C, Munkarah A, Elshaikh MA.

Gynecol Obstet Invest. 2019;84(3):283-289. doi: 10.1159/000495613. Epub 2018 Dec 12.

PMID:
30540995
2.

The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.

Qu XM, Velker VM, Leung E, Kwon JS, Elshaikh MA, Kong I, Logie NA, Mendez LC, van der Putten LJ, Donovan EK, Munkarah AR, Wiebe EM, Parra-Herran C, Warner A, Louie AV, D'Souza DP.

Gynecol Oncol. 2018 May;149(2):283-290. doi: 10.1016/j.ygyno.2018.03.002. Epub 2018 Mar 12.

PMID:
29544706
3.

Does Age-Adjusted Charlson Comorbidity Score Impact Survival Endpoints in Women with Federation of Gynecology and Obstetrics-Stage III Endometrial Cancer?

Ghanem AI, Modh A, Burmeister C, Munkarah AR, Elshaikh MA.

Gynecol Obstet Invest. 2018;83(3):290-298. doi: 10.1159/000487047. Epub 2018 Mar 8.

PMID:
29518778
4.

Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity.

Xia H, Wang W, Crespo J, Kryczek I, Li W, Wei S, Bian Z, Maj T, He M, Liu RJ, He Y, Rattan R, Munkarah A, Guan JL, Zou W.

Sci Immunol. 2017 Nov 17;2(17). pii: eaan4631. doi: 10.1126/sciimmunol.aan4631.

5.

Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.

Abdulfatah E, Sakr S, Thomas S, Al-Wahab Z, Mutch DG, Dowdy S, Bandyopadhyay S, Munkarah A, Elshaikh M, Morris R, Ali-Fehmi R.

Int J Gynecol Cancer. 2017 Oct;27(8):1714-1721. doi: 10.1097/IGC.0000000000001050.

6.

Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells.

Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, Giri S, Munkarah A, Rattan R.

Sci Rep. 2017 Aug 18;7(1):8760. doi: 10.1038/s41598-017-09206-0.

7.

Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.

Mert I, Chhina J, Allo G, Dai J, Seward S, Carey MS, Llaurado M, Giri S, Rattan R, Munkarah AR.

Gynecol Oncol. 2017 Aug;146(2):319-326. doi: 10.1016/j.ygyno.2017.05.019. Epub 2017 May 22.

PMID:
28545687
8.

External pelvic and vaginal irradiation vs. vaginal irradiation alone as postoperative therapy in women with early stage uterine serous carcinoma: Results of a National Cancer Database analysis.

Modh A, Burmeister C, Munkarah AR, Elshaikh MA.

Brachytherapy. 2017 Jul - Aug;16(4):841-846. doi: 10.1016/j.brachy.2017.04.237. Epub 2017 May 13.

PMID:
28511891
9.

Involvement and comfort of gynecologic oncologists in the treatment of pediatric, adolescent, and young adult patients with gynecologic malignancies.

Winer I, Patel D, Dalton V, Johnston C, Quint EH, Zochowski M, Munkarah A, Morris R, Haefner H.

Int J Gynaecol Obstet. 2017 Aug;138(2):177-182. doi: 10.1002/ijgo.12200. Epub 2017 May 30.

PMID:
28485838
10.

A Wireless Audio System Improves Teamwork and Communication in Robotic Laparoscopic Surgery.

Tsafrir Z, Janosek-Albright K, Aoun J, Abd-El-Barr AE, Schiff L, Talukdar S, Menon M, Munkarah A, Theoharis E, Eisenstein D.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S8. doi: 10.1016/j.jmig.2015.08.030. Epub 2015 Oct 15. No abstract available.

PMID:
27679344
11.

Predictive Capacity of 3 Comorbidity Indices in Estimating Survival Endpoints in Women With Early-Stage Endometrial Carcinoma.

Al Feghali KA, Robbins JR, Mahan M, Burmeister C, Khan NT, Rasool N, Munkarah A, Elshaikh MA.

Int J Gynecol Cancer. 2016 Oct;26(8):1455-60. doi: 10.1097/IGC.0000000000000802.

PMID:
27488218
12.

Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.

Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.

Gynecol Oncol. 2016 Aug;142(2):323-31. doi: 10.1016/j.ygyno.2016.06.005. Epub 2016 Jun 16.

PMID:
27282964
13.

Cancer and the world's poor: What's a gynecologic cancer specialist to do?

Randall TC, Goodman A, Schmeler K, Durfee J, Pareja R, Munkarah A, Rulisa S, Ghebre R, Trimble EL, Chuang L.

Gynecol Oncol. 2016 Jul;142(1):6-8. doi: 10.1016/j.ygyno.2016.05.018. Epub 2016 May 24.

PMID:
27210817
14.

Predictors of Survival After Recurrence in Women With Early-Stage Endometrial Carcinoma.

Xu Y, Burmeister C, Hanna RK, Munkarah A, Elshaikh MA.

Int J Gynecol Cancer. 2016 Jul;26(6):1137-42. doi: 10.1097/IGC.0000000000000733.

PMID:
27206283
15.

Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, Zou W.

Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28.

16.

Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.

Rana S, Blowers EC, Tebbe C, Contreras JI, Radhakrishnan P, Kizhake S, Zhou T, Rajule RN, Arnst JL, Munkarah AR, Rattan R, Natarajan A.

J Med Chem. 2016 May 26;59(10):5121-7. doi: 10.1021/acs.jmedchem.6b00400. Epub 2016 Apr 26.

17.

Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.

Munkarah A, Mert I, Chhina J, Hamid S, Poisson L, Hensley-Alford S, Giri S, Rattan R.

Gynecol Oncol. 2016 Apr;141(1):72-9. doi: 10.1016/j.ygyno.2016.02.026.

PMID:
27016232
18.

Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.

Hijaz M, Das S, Mert I, Gupta A, Al-Wahab Z, Tebbe C, Dar S, Chhina J, Giri S, Munkarah A, Seal S, Rattan R.

BMC Cancer. 2016 Mar 15;16:220. doi: 10.1186/s12885-016-2206-4.

19.

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, Kotarski J, Tarkowski R, Dou Y, Cho K, Hensley-Alford S, Munkarah A, Liu R, Zou W.

Nature. 2015 Nov 12;527(7577):249-53. doi: 10.1038/nature15520. Epub 2015 Oct 26.

20.

Obesity and Lymphovascular Invasion in Women with Uterine Endometrioid Carcinoma.

Kamal M, Burmeister C, Zhang Z, Munkarah A, Elshaikh MA.

Anticancer Res. 2015 Jul;35(7):4053-7.

PMID:
26124354
21.

Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction.

Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R.

Oncotarget. 2015 May 10;6(13):10908-23.

22.

A metabolomic approach to identifying platinum resistance in ovarian cancer.

Poisson LM, Munkarah A, Madi H, Datta I, Hensley-Alford S, Tebbe C, Buekers T, Giri S, Rattan R.

J Ovarian Res. 2015 Mar 26;8:13. doi: 10.1186/s13048-015-0140-8.

23.

The prognostic significance of histologic type in early stage cervical cancer - A multi-institutional study.

Winer I, Alvarado-Cabrero I, Hassan O, Ahmed QF, Alosh B, Bandyopadhyay S, Thomas S, Albayrak S, Talukdar S, Al-Wahab Z, Elshaikh MA, Munkarah A, Morris R, Ali-Fehmi R.

Gynecol Oncol. 2015 Jun;137(3):474-8. doi: 10.1016/j.ygyno.2015.02.005. Epub 2015 Feb 10.

PMID:
25677061
24.

Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.

Mahdi H, Elshaikh MA, DeBenardo R, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, Moslemi-Kebria M.

Gynecol Oncol. 2015 May;137(2):239-44. doi: 10.1016/j.ygyno.2015.01.544. Epub 2015 Jan 29.

PMID:
25641568
25.

Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.

Mahdi H, Rose PG, Elshaikh MA, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, DeBenardo R.

Gynecol Oncol. 2015 Mar;136(3):529-33. doi: 10.1016/j.ygyno.2014.12.034. Epub 2015 Jan 7.

PMID:
25575483
26.

Tumor size is an independent predictor of lymph node metastasis and survival in early stage endometrioid endometrial cancer.

Mahdi H, Munkarah AR, Ali-Fehmi R, Woessner J, Shah SN, Moslemi-Kebria M.

Arch Gynecol Obstet. 2015 Jul;292(1):183-90. doi: 10.1007/s00404-014-3609-6. Epub 2014 Dec 31.

PMID:
25549769
27.

Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Alford SH, Rattan R, Buekers TE, Munkarah AR.

Cancer. 2015 Feb 1;121(3):441-7. doi: 10.1002/cncr.28952. Epub 2014 Dec 22.

28.

Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study.

Elshaikh MA, Al-Wahab Z, Mahdi H, Albuquerque K, Mahan M, Kehoe SM, Ali-Fehmi R, Rose PG, Munkarah AR.

Gynecol Oncol. 2015 Feb;136(2):235-9. doi: 10.1016/j.ygyno.2014.12.012. Epub 2014 Dec 12.

PMID:
25511158
29.

Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?

Winer I, Ahmed QF, Mert I, Bandyopadhyay S, Cote M, Munkarah AR, Hussein Y, Al-Wahab Z, Elshaikh MA, Alosh B, Schultz DS, Mahdi H, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.

Int J Gynecol Pathol. 2015 Jan;34(1):47-56. doi: 10.1097/PGP.0000000000000113.

PMID:
25473753
30.

Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.

Belotte J, Fletcher NM, Alexis M, Morris RT, Munkarah AR, Diamond MP, Saed GM.

Reprod Sci. 2015 Jan;22(1):38-46. doi: 10.1177/1933719114542021. Epub 2014 Jul 18.

31.

Dietary energy balance modulates ovarian cancer progression and metastasis.

Al-Wahab Z, Tebbe C, Chhina J, Dar SA, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R.

Oncotarget. 2014 Aug 15;5(15):6063-75.

32.

Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.

Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, Munkarah AR, Rattan R.

Oncotarget. 2014 Jul 15;5(13):4746-64.

33.

The influence of comorbid conditions on racial disparities in endometrial cancer survival.

Ruterbusch JJ, Ali-Fehmi R, Olson SH, Sealy-Jefferson S, Rybicki BA, Hensley-Alford S, Elshaikh MA, Gaba AR, Schultz D, Munkarah AR, Cote ML.

Am J Obstet Gynecol. 2014 Dec;211(6):627.e1-9. doi: 10.1016/j.ajog.2014.06.036. Epub 2014 Jun 19.

34.

Racial disparities in uterine clear cell carcinoma: a multi-institution study.

Al-Wahab ZR, Kumar S, Mutch DG, Dowdy SC, Hensley SA, Wang Y, Mahdi H, Ali-Fehmi R, Morris RT, Elshaikh M, Munkarah AR.

Int J Gynecol Cancer. 2014 Mar;24(3):541-8. doi: 10.1097/IGC.0000000000000068.

PMID:
24552897
35.

Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.

Elshaikh MA, Vance S, Suri JS, Mahan M, Munkarah A.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):351-6. doi: 10.1016/j.ijrobp.2013.11.003.

PMID:
24411608
36.

Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.

Ahmed Q, Hussein Y, Hayek K, Bandyopadhyay S, Semaan A, Abdul-Karim F, Al-Wahab Z, Munkarah AR, Elshaikh MA, Alosh B, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.

Gynecol Oncol. 2014 Feb;132(2):372-6. doi: 10.1016/j.ygyno.2013.11.011. Epub 2013 Nov 19.

PMID:
24262874
37.

Improved survival of baby boomer women with early-stage uterine cancer: A Surveillance, Epidemiology and End Results (SEER) Study.

Elshaikh MA, Ruterbusch J, Cote ML, Cattaneo R 2nd, Munkarah AR.

Anticancer Res. 2013 Nov;33(11):4983-7.

PMID:
24222139
38.

Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.

Mahdi H, Moslemi-Kebria M, Levinson KL, Gojayev A, Lockhart D, Ali-Fehmi R, Munkarah AR.

Int J Gynecol Cancer. 2013 Sep;23(7):1226-30. doi: 10.1097/IGC.0b013e3182856736.

PMID:
23736258
39.

Risk of postoperative venous thromboembolism after minimally invasive surgery for endometrial and cervical cancer is low: a multi-institutional study.

Kumar S, Al-Wahab Z, Sarangi S, Woelk J, Morris R, Munkarah A, Dowdy SC, Mariani A, Cliby W.

Gynecol Oncol. 2013 Jul;130(1):207-12. doi: 10.1016/j.ygyno.2013.04.024. Epub 2013 Apr 20.

PMID:
23612315
40.

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.

Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, Morris R, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, Batchu RB.

Cancer Lett. 2013 Aug 9;336(1):53-60. doi: 10.1016/j.canlet.2013.04.012. Epub 2013 Apr 18.

PMID:
23603558
41.

Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study.

Semaan A, Mert I, Munkarah AR, Bandyopadhyay S, Mahdi HS, Winer IS, Nucci MR, Hussein Y, Quershi F, Hayek K, Tabassum F, Alosh B, Schultz DS, Cote ML, Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.

Int J Gynecol Pathol. 2013 Mar;32(2):181-7. doi: 10.1097/PGP.0b013e318273fc55. Erratum in: Int J Gynecol Pathol. 2013 Jul;32(4):432.

PMID:
23370657
42.

A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.

Al-Badawi IA, Munkarah AR, Tulbah A, Babic II, Al Husaini H, Ahmad S.

Int J Gynecol Cancer. 2013 Mar;23(3):456-60. doi: 10.1097/IGC.0b013e318284aafe.

PMID:
23360812
43.

Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families.

Kaplun L, Fridman AL, Chen W, Levin NK, Ahsan S, Petrucelli N, Barrick JL, Gold R, Land S, Simon MS, Morris RT, Munkarah AR, Tainsky MA.

Biomark Insights. 2012;7:151-7. doi: 10.4137/BMI.S10815. Epub 2012 Dec 12.

44.

Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma.

Robbins JR, Siddiqui MS, Al-Wahab Z, Laser B, Lu M, Ali-Fehmi R, Munkarah A, Elshaikh MA.

Eur J Gynaecol Oncol. 2012;33(5):449-54.

PMID:
23185785
45.

Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study.

Winer I, Mahdi H, Bandyopadhyay S, Semaan A, Van de Vijver KK, Nucci MR, Abdul-Karim F, Hussein Y, Qureshi F, Hayek K, Alosh B, Schulz D, Cote M, Munkarah A, Morris R, Oliva E, Ali-Fehmi R.

Gynecol Oncol. 2013 Feb;128(2):316-21. doi: 10.1016/j.ygyno.2012.10.027. Epub 2012 Nov 5.

PMID:
23138135
46.

The impact of race on outcomes of patients with early stage uterine endometrioid carcinoma.

Elshaikh MA, Munkarah AR, Robbins JR, Laser BS, Bhatt N, Cogan C, Siddiqui F.

Gynecol Oncol. 2013 Feb;128(2):171-4. doi: 10.1016/j.ygyno.2012.10.016. Epub 2012 Oct 23.

PMID:
23103929
47.

Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.

Cote ML, Atikukke G, Ruterbusch JJ, Olson SH, Sealy-Jefferson S, Rybicki BA, Alford SH, Elshaikh MA, Gaba AR, Schultz D, Haddad R, Munkarah AR, Ali-Fehmi R.

Int J Gynecol Cancer. 2012 Oct;22(8):1367-72.

48.

The impact of income on clinical outcomes in FIGO stages I to II endometrioid adenocarcinoma of the uterus.

Robbins JR, Mahan MG, Krajenta RJ, Munkarah AR, Elshaikh MA.

Am J Clin Oncol. 2013 Dec;36(6):625-9. doi: 10.1097/COC.0b013e31825eb386.

PMID:
22892431
49.

Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.

Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi R.

Gynecol Oncol. 2013 Feb;128(2):344-8. doi: 10.1016/j.ygyno.2012.07.128. Epub 2012 Aug 4.

PMID:
22871469
50.

Prognostic impact of lymphadenectomy in uterine serous cancer.

Mahdi H, Kumar S, Al-Wahab Z, Ali-Fehmi R, Munkarah AR.

BJOG. 2013 Mar;120(4):384-91. doi: 10.1111/j.1471-0528.2012.03431.x. Epub 2012 Jul 25.

Supplemental Content

Loading ...
Support Center